Sustainability at Wasteless Bio
At Wasteless Bio, we focus on preventing the >20% of Life Science consumables that go unused—often destined for landfill or disposal. With the industry responsible for approximately 9% of global emissions, waste reduction and better resource use are critical. By reselling products that would otherwise go to waste, we help companies minimise both physical waste and Scope 3 emissions across their supply chains.

-
1
Extending Product Life Cycles
Reselling keeps items in circulation longer. Instead of being thrown away when no longer needed by their original owners, these products find new users—cutting down on production of new items and reducing environmental impact.
-
2
Reducing Demand for New Resources
Less demand for newly manufactured items means fewer raw materials, less energy used, and a smaller carbon footprint. Each product that's reused avoids the emissions cost of making another one from scratch.
-
3
Minimising Waste and Disposal Emissions
Unused products can end up in landfill or incineration, generating emissions and pollution. Reselling those products prevents unnecessary disposal and associated emissions—especially important in the life sciences sector, where items can be resource-intensive to produce.
-
4
Encouraging a Circular Economy
By giving these products a second life, we create a loop where valuable supplies stay in use for longer. This approach helps companies close the loop in their supply chains, significantly cutting down on waste and limiting Scope 3 emissions tied to overproduction.
-
5
Promoting Sustainable Consumption Practices
Making it easy to sell and buy unused items pushes labs and companies to purchase only what they need, manage inventory more efficiently, and carefully plan usage. Ultimately, these practices reduce both material and emissions footprints.
-
6
Decreasing Emissions from End-of-Life Products
Many lab items have strict shelf lives or specific disposal protocols. By reselling them before they expire, we extend usability and avoid the carbon cost of early disposal—minimising landfill and incineration emissions.
Mini Case Study: Sanofi using Wasteless Bio
Goal: Reduce Scope 3 emissions by 30% by 2030
If Sanofi were to purchase 5% of their goods and resell 20% of their non-hazardous waste on WL they could reduce their Scope 3 emissions by >4%. WL is likely the only "for profit" mechanism to lower the industry's environmental footprint.
Industry Leaders Commitments
- 1 "Pfizer's scope 3 (value chain) GHG footprint is four times that associated with the company's direct operations (scope 1)."
- 2 Building on 20+ years of climate action, committed to Net Zero by 2040, reducing company emissions by 95% and value chain emissions by 90%.

- 1 Reduce the amount of waste sent for disposal by half by 2025 (vs 2016)
- 2 Become carbon neutral across scope 1, 2 and 3 emissions by 2030

- 1 By 2030 achieve a circularity rate of 70% across the organization
- 2 <20% of global waste will be sent to landfills and incinerators by 2025
- 3 Over 50% of sites will send zero waste to landfill by 2025

- 1 Targeting >90% of waste to be reused, recycled or recovered by 2025
- 2 Committed to reduce scope 3 GHG emissions by 30% by 2030 from 2019

- 1 Zero operational waste, including eliminating single-use plastics, by 2030
- 2 100% of waste repurposed for beneficial use by 2030
- 3 Reduce absolute scope 3 GHG emissions by 80% by 2030 vs 2020
Our ultimate aim is to boost collaboration, cut operational waste, and lower the barrier to new drug development.